What You Should Know:
– MedeAnalytics, a healthcare enterprise data enrichment platform and analytics software-as-a-service (SaaS) leader announced its partnership with DecisionRx, a technology-enabled healthcare services company specializing in medication therapy optimization (MTO).
– The collaboration will allow DecisionRx to expand its ability to quantify and communicate the clinical and economic impact of its work with payers and providers under value-based care contracts, by incorporating the analytical capabilities of MedeAnalytics’ Health Fabric™.
Costly Challenge of Today’s Medication Failure
DecisionRx’s MTO platform enables personalized prescribing decisions informed by data science, clinical guidelines, and pharmacist expertise. The platform is designed to deliver measurable savings and improve outcomes for patients at high risk of medication failure, a common issue that often leads to increased costs for payers, providers, and patients.
Medication therapy optimization has shown significant financial benefits:
- It can reduce the total annual cost of care by over $3,600 for Medicare patients.
- It can save $1,200 for patients under the age of 65.
Enhanced Value-Based Care
By leveraging MedeAnalytics’ industry-leading outcomes analysis capabilities, DecisionRx will be able to:
- Quantify the ROI of its clinical interventions using real-world data.
- Track cost savings and utilization reductions across populations.
- Measure and report performance on quality and value-based metrics.
- Seamlessly communicate insights with payer and provider stakeholders.
- Accelerate the adoption of its platform within value-based care frameworks.
“DecisionRx is addressing a critical and costly gap in healthcare, medication failure,” said Steve Grieco, CEO of MedeAnalytics. “We’re proud to support their mission by equipping their team with robust, scalable outcomes analytics to track savings, optimize interventions, and advance their unique value-based care approach.”
